NCT04416438View on ClinicalTrials.gov

COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias

CompletedOBSERVATIONAL
Enrollment

1,793

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

September 1, 2022

Conditions
Myeloproliferative NeoplasmCOVID-19 Infection
Trial Locations (1)

75475

Paris Saint Louis, Paris

All Listed Sponsors
collaborator

French Intergroup of Myeloproliferative syndromes

UNKNOWN

lead

French Innovative Leukemia Organisation

OTHER

NCT04416438 - COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias | Biotech Hunter | Biotech Hunter